First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. - Wikidata - wikimedia - TriplyDB

First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany.

First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany.

http://www.wikidata.org/entity/Q38421534

about

Pilot studies for development of an HIV subtype panel for surveillance of global diversity.Quality and Safety in Blood Supply in 2010 Treatment of Ebola virus infection with antibodies from reconvalescent donors.Transmission of human immunodeficiency virus infection by renal transplantation.Molecular virology in transfusion medicine laboratory.Implementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres.Human Immunodeficiency Virus (HIV).Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus.Risk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany.Molecular HIV screening.High sensitivity detection of HIV-1 using two genomic targets compared with single target PCR.Motivations for donating and attitudes toward screening policies in US blood donors with viral infection.Detection of emergent strains of West Nile virus with a blood screening assay.Evaluation of the Procleix Ultrio Elite Assay and the Panther-System for Individual NAT Screening of Blood, Hematopoietic Stem Cell, Tissue and Organ Donors.Transmission of human immunodeficiency virus Type-1 by fresh-frozen plasma treated with methylene blue and light.[Human immunodeficiency virus: position of Blood Working Group of the Federal Ministry of Health].Inclusion of human immunodeficiency virus Type 2 (HIV-2) in a multiplex transcription-mediated amplification assay does not affect detection of HIV-1 and hepatitis B and C virus genotypes: a multicenter performance evaluation study.Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma.Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions.Preanalytical stability of HIV-1 and HCV RNA: impact of storage and plasma separation from cells on blood donation testing by NAT.How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing.Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk.Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets.A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays.

P2860

Q30514155-54EDD510-04EB-4307-9777-AA63F66A5007 Q33929726-43B28885-F91C-4061-8241-614A8FF98DDD Q35130375-1CB6CCD4-8204-47E1-906F-AD36234D4E86 Q36082312-1D2FF6AF-22F7-4F2B-972E-C2D21B20DD50 Q36766449-083E5CF2-945E-4707-BEB6-7177A4727D27 Q37045800-7854ACB0-A82B-4D62-8CA9-2925C36C8AA4 Q37045832-8A471659-7417-4959-8949-86E17C7468DF Q37618604-A95A2F93-C878-44C1-BC7B-A893F5F48676 Q37630304-41FEB420-1719-4BF8-94CC-6C26D8F32D14 Q38142249-275EEB8F-CE8C-4F41-A451-E9BBD6543D30 Q38295260-4DF304D4-C733-440A-8B7D-E61D19AF1B03 Q39649596-CC0F135B-8956-42B6-9DD1-480B18BA68F9 Q40127918-8B2763C3-5F35-4CEF-ABEE-8AAA022ACB17 Q40656078-5AC5AEA7-3210-4B31-8959-3037783702EE Q40903377-B5014F7A-8EC4-439D-B2E4-B9AF37469B8E Q40942917-80B9065A-D7F6-430B-A2A9-E91EB913E20D Q41647666-A70CFD8C-F0D4-4E8E-A035-1CD50DD7B7F4 Q42220047-C69851A4-FA2F-4DA2-8AF2-D7E4176F829F Q42981169-DB6D319F-30E5-49C3-B3DA-95F69EB1E06C Q42987806-D556DA3F-FDEF-48A4-BF72-39CEF7A6B49B Q43001633-E4FC6373-625C-4975-B1DD-7B666ACD3F3B Q45350673-2C327A7F-332A-4C9C-A934-C618A9BFACD8 Q45362712-F4F6DA2F-6952-4D8A-A29A-E67FDCD78B4B Q45364475-46B90B8B-EAF9-4E7A-ACE0-5F1BCAE623BD Q45371172-FDAC0529-EE28-439C-AF5A-A14C212DE144

P2860

First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany.

http://www.wikidata.org/entity/Q38421534

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

First transmission of human im ...... eic acid screening in Germany.

@en

type

label

First transmission of human im ...... eic acid screening in Germany.

@en

prefLabel

First transmission of human im ...... eic acid screening in Germany.

@en

P1433

Q38421534-DDBF94E0-E0CB-41EE-81B9-388BEC434783

P1476

Q38421534-5BF2F738-546B-4371-850E-8E5159F0DF82

P2093

Q38421534-10C9A93A-1B89-4C5A-B2B3-6A0B8F0FA55E

Q38421534-2EFCEE44-D437-435B-A3B6-BB6E7067729A

Q38421534-3460CD55-DEE9-4830-BA8C-DA8C164EA90B

Q38421534-357F79A4-6E57-46AA-A9BD-342EDD98F414

Q38421534-52EDE28F-D0F4-4C87-8DE9-31BF9D253902

Q38421534-54F00A34-FB1B-4931-8F28-AD753FDFC3B8

Q38421534-63AA31BF-3297-4D2F-851F-F593EF896F1C

Q38421534-6F67C0AD-63F5-48AD-B37A-21CD300F8FF6

Q38421534-89D43C07-EC45-42CE-9545-184D369622C2

Q38421534-8E9F1B2C-7E6C-430C-887D-707628E3C558

P2860

Q38421534-12071438-2ABA-427D-BC0E-71BCA88B0FA3

Q38421534-16C57A23-750B-4780-A8FA-817113BD1F4A

Q38421534-170B9339-1C75-45A1-AB78-E226BFCE42B5

Q38421534-245BEDE7-1978-4FC7-A126-CB7302463899

Q38421534-265AE093-4B50-4930-80C4-85503EC1B19B

Q38421534-3D0C117A-74B4-49B0-B86D-20A32BCC4B67

Q38421534-40EA09BF-8590-49AB-A0D7-A891D8D12B45

Q38421534-4DEEC0DE-2245-4E53-9767-F6BF043EC822

Q38421534-4E80D8AE-42BE-4BA8-8193-409C2160D173

Q38421534-71869BB1-6562-4F9B-AA70-052E6CABDDA5

P304

Q38421534-15D30116-0256-457D-ADF8-4BB3D4C4E103

P31

Q38421534-187CC7DB-74A0-463C-BB44-92E38E782E7E

P356

Q38421534-4EAA599D-E4EC-45ED-A140-9F72F860B378

P433

Q38421534-CF53464D-1EE9-4B8A-8E8C-BCCA2E6E3D3E

P478

Q38421534-0B0BD24D-6479-42FD-A606-37A74DA8CA79

P577

Q38421534-BADF3095-9F5D-49E3-907A-19498B29728A

P698

Q38421534-B87DEDBB-07E5-4998-8F9B-637282DB5DB7

P921

Q38421534-1FBB0ABA-9580-44FE-AD43-87EFD1E3D902

P356

J.1537-2995.2009.02203.X

P1433

P1476

First transmission of human im ...... eic acid screening in Germany.

@en

P2093

Andreas Karl

http://www.w3.org/2001/XMLSchema#string

Annemarie Berger

http://www.w3.org/2001/XMLSchema#string

B Karsten Tischer

http://www.w3.org/2001/XMLSchema#string

C Micha Nübling

http://www.w3.org/2001/XMLSchema#string

Erhard Seifried

http://www.w3.org/2001/XMLSchema#string

Geert Geusendam

http://www.w3.org/2001/XMLSchema#string

Hans Wilhelm Doerr

http://www.w3.org/2001/XMLSchema#string

Heinz A Horst

http://www.w3.org/2001/XMLSchema#string

Helmut Fickenscher

http://www.w3.org/2001/XMLSchema#string

Holger F Rabenau

http://www.w3.org/2001/XMLSchema#string

P2860

TaqMan 5'-nuclease human immunodeficiency virus type 1 PCR assay with phage-packaged competitive internal control for high-throughput blood donor screening.

Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.

The German experience with NAT.

Multicenter evaluation of a new, automated enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies and antigen.

Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing.

Emerging infectious diseases that threaten the blood supply.

PROCLEIX West Nile virus assay based on transcription-mediated amplification.

Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain.

Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels

Dynamics of viremia in early hepatitis C virus infection.

P304

1836-1844

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1537-2995.2009.02203.X

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19453990

http://www.w3.org/2001/XMLSchema#string

P921